You are here

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

Last updated on November 15, 2018

FOR MORE INFORMATION
Study Location
Scottsdale Healthcare Hospitals DBA HonorHealth
Scottsdale, Arizona, 85258 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic Pancreatic Ductal Adenocarcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically or cytologically-confirmed metastatic pancreatic ductal adenocarcinoma.

- Availability of a tumor tissue specimen. If no archived tumor tissue is available,
then a de novo biopsy is required for patient participation.

- Karnofsky Performance Status 70 or greater.

- Adequate Bone Marrow, Renal, and Liver Function.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior treatment with a CDK 4/6 inhibitor.

- Prior treatment with nab-P for the treatment of metastatic disease.

- Patients with known CNS metastases, carcinomatous meningitis, or leptomeningeal
disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth.

- Diagnosis of any other malignancy within 3 years prior to enrollment, except for
adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of
the cervix.

- QTc >480 msec, or family or personal history of long or short QT syndrome, Brugada
syndrome or known history of QTc prolongation, or Torsade de Pointes.

- Uncontrolled electrolyte disorders.

- Cardiac or pulmonary disorders within 6 months of enrollment.

- Known human immunodeficiency virus infection.

- History of interstitial lung disease or pneumonitis.

- Other severe acute or chronic medical or psychiatric condition that may increase the
risk associated with study participation.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to nab-P.

- Difficulty swallowing capsules or requirement for a feeding tube.

- Previous high-dose chemotherapy requiring stem cell rescue.

- Pregnant female patients; breastfeeding female patients; male patients with partners
currently pregnant.

- Active inflammatory or other gastrointestinal disease,

- Active bleeding disorder in the past 6 months.

- Patients treated within the last 7 days prior to the start of IP with strong/moderate
CYP3A4 inhibitors, strong/moderate CYP3A4 inducers, CYP2C8 inhibitors, strong/moderate
CYP2C8 inducers, or drugs that are known to prolong the QT interval.

NCT02501902
Pfizer
Recruiting
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Locally Advanced or Metastatic Solid Tumors, BRCA 1 Genes
NCT03565991
All Genders
18+
Years
Multiple Sites
Metastatic Pancreatic Ductal Adenocarcinoma
NCT02501902
All Genders
18+
Years
Multiple Sites
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
An Open-label Phase Ib Study Of Palbociclib (Oral Cdk 4/6 Inhibitor) Plus Abraxane (Registered) (Nab-paclitaxel) In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately 30-60 patients are expected to be enrolled in the overall study.

The study has 2 parts:

? Part A (Dose-Escalation Cohorts): Consecutive cohorts of patients will receive escalating doses of oral palbociclib in combination with intravenous nab-P in 28-day cycles, in order to estimate the MTD(s) of the combination. The starting doses will be 75 mg palbociclib, and 100 mg/m2 nab-P. The observation period for dose-limiting toxicities (DLTs) will be from Day 1 to Day 28. Pharmacokinetic (PK) and pharmacodynamic (PD) properties of palbociclib and nab-P will also be assessed. Up to approximately 30 patients will be enrolled. The criteria for dose escalation will be based on a modified toxicity probability interval (mTPI) method.

? Part B [MTD Expansion Cohort(s)]: When the MTD(s) of palbociclib plus nab-P has been estimated with confidence, enrollment will proceed into 1 or 2 MTD expansion cohort(s) of up to 20 patients each at the MTD(s). The objective of the MTD expansion cohort(s) will be to provide additional information on safety, tolerability, biomarkers, PD activity, and PK/PD relationship for the combination regimen in order to determine the RP2D. The MTD expansion cohort(s) will only enroll patients who have not received previous treatment for their metastatic disease in order to evaluate preliminary activity of the combination in the target patient population.

All patients (in Part A and B) will receive nab-P intravenously once weekly for 3 weeks out of each 28-day cycle. Palbociclib oral dosing will be once daily on Days 1-21 of each 28-day cycle. To allow for PK evaluation of nab-P administered alone, nab-P will be administered on Day -2 for Cycle 1 only. Subsequent cycles will administer both nab-P and palbociclib on Day 1. Alternate dosing schedules for palbociclib may be explored based on emerging PK, PD, and safety data.

Patients will be treated as long as they are clinically benefiting from investigational product without unacceptable toxicity, objective disease progression, or withdrawal of consent. A modified visit schedule will be implemented for patients who are on investigational product for more than 2 years.

Interventional
Phase 1
Masking: None (Open Label)
Primary Purpose: Treatment
Metastatic Pancreatic Ductal Adenocarcinoma
  • Drug: Palbociclib
    Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
    Other Name: Ibrance
  • Drug: Nab-Paclitaxel
    Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
    Other Name: Abraxane
Experimental: Palbociclib + Nab-Paclitaxel
Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
Interventions:
  • Drug: Palbociclib
  • Drug: Nab-Paclitaxel
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
September 18, 2018
September 18, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically-confirmed metastatic pancreatic ductal adenocarcinoma.
  • Availability of a tumor tissue specimen. If no archived tumor tissue is available, then a de novo biopsy is required for patient participation.
  • Karnofsky Performance Status 70 or greater.
  • Adequate Bone Marrow, Renal, and Liver Function.

Exclusion Criteria:

  • Prior treatment with a CDK 4/6 inhibitor.
  • Prior treatment with nab-P for the treatment of metastatic disease.
  • Patients with known CNS metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth.
  • Diagnosis of any other malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
  • QTc >480 msec, or family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.
  • Uncontrolled electrolyte disorders.
  • Cardiac or pulmonary disorders within 6 months of enrollment.
  • Known human immunodeficiency virus infection.
  • History of interstitial lung disease or pneumonitis.
  • Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-P.
  • Difficulty swallowing capsules or requirement for a feeding tube.
  • Previous high-dose chemotherapy requiring stem cell rescue.
  • Pregnant female patients; breastfeeding female patients; male patients with partners currently pregnant.
  • Active inflammatory or other gastrointestinal disease,
  • Active bleeding disorder in the past 6 months.
  • Patients treated within the last 7 days prior to the start of IP with strong/moderate CYP3A4 inhibitors, strong/moderate CYP3A4 inducers, CYP2C8 inhibitors, strong/moderate CYP2C8 inducers, or drugs that are known to prolong the QT interval.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Spain,   United States
Switzerland
 
NCT02501902
A5481059
2015-001307-31 ( EudraCT Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Celgene
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now